Sunshine Biopharma, Inc.
SBFM
$1.25
$0.032.46%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -13.94% | 84.21% | 86.66% | 84.98% | 83.15% |
| Total Depreciation and Amortization | 49.80% | 59.38% | 93.62% | 176.58% | 492.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -99.93% | -99.93% | -99.93% | -100.00% |
| Change in Net Operating Assets | -72.76% | -47,756.44% | -4,772.59% | -303.46% | -240.06% |
| Cash from Operations | -42.81% | -41.79% | -21.24% | -74.49% | -67.20% |
| Capital Expenditure | -1,915.82% | -77.95% | -2.40% | 25.21% | 57.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -200.00% | -- |
| Cash Acquisitions | -- | -- | -- | 100.01% | 100.00% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15.66% | -886,600.00% | -2,704.93% | -363.56% | -639.56% |
| Cash from Investing | -253.73% | 86.28% | 90.28% | 92.02% | 95.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 3.44% | -25.68% | -95.90% | 93.47% |
| Issuance of Common Stock | 195.19% | 155.85% | 109.51% | -56.53% | -90.60% |
| Repurchase of Common Stock | -480.24% | -480.24% | -526.28% | -526.28% | -446.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 171.18% | 429.86% | 270.62% | -64.66% | -91.32% |
| Foreign Exchange rate Adjustments | -321.27% | -89.73% | -287.06% | -64.48% | 156.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -19.37% | 69.42% | 62.63% | -130.41% | -127.98% |